Newswire and Healthcare Information

Iselin NJ, August 29, 2008 – Pharmos Corporation (Nasdaq: PARS) today announced that effective October 3 1, 2008 it will cease operations in Rehovot, Israel, and manage those activities currently based in Rehovot out of the Company’s US headquarters in Iselin, New Jersey. The research programs in Israel are the CB2 receptor selective library of compounds, including preclinical development of PRS-639,058 for neuropathic pain. Additionally the […]

Iselin NJ, August 7, 2008 – Pharmos Corporation (Nasdaq: PARS) today reported results for the second quarter ended June 30,2008. The Company recorded a net loss of $2.7 million, or $0.10 per share, for the second quarter 2008 compared to a net loss of $4.6 million, or $0.18 per share, in the second quarter 2007. Cash and cash equivalents totaled $9.0 million at June 30,2008. The […]

Iselin NJ, May 14, 2008 – Pharmos Corporation (Nasdaq: PARS) announced today that its President and Chief Financial Officer, S. Colin Neill, will present at the Rodman & Renshaw 5th Annual Global Healthcare Conference on Monday, May 19, 2008 at 5:15 PM Central Europe Daylight Time (GMT +2:00, or 11:15 AM Eastern Daylight Time). The conference is taking place May 19-20, 2008 at Le Meridien Beach […]

Iselin NJ, May 8, 2008 – Pharmos Corporation (Nasdaq: PARS) today reported results for the first quarter ended March 31, 2008. The Company recorded a net loss of $3.6 million, or $0.14 per share, for the first quarter 2008 compared to a net loss of $4.8 million, or $0.19 per share, in the first quarter 2007. Cash and short-term investments totaled $11.3 million at March 31, […]

Iselin NJ, February 28, 2008 – Pharmos Corporation (Nasdaq: PARS) today reported financial results for the fourth quarter and twelve-month period and ended December 31, 2007. Fourth Quarter ended December 31, 2007 For the fourth quarter ended December 31, 2007, Pharmos reported a net loss of $2.7 million, or $0.11 per share compared to a net loss of $23.8 million, or $1.00 per share for the […]

Iselin NJ, January 3, 2008 – Pharmos Corporation (Nasdaq: PARS) announced today certain changes in its Board of Directors and Management, effective immediately. Board Changes Robert F. Johnston has been elected to the Board as Executive Chairman. Haim Aviv, Ph.D., David Schlachet and Mony Ben Dor have retired from the Board. The Pharmos Board now consists of seven directors — Robert F. Johnston, Chairman, Anthony B. […]

Iselin NJ, January 3, 2008 – Pharmos Corporation (Nasdaq: PARS) announced today that it has completed an initial closing of a private placement of its 10% Convertible Debentures due November 2012. At the initial closing the Company issued $4,000,000 principal amount of the Debentures, at par, and received gross proceeds in the same amount. The purchasers consisted of certain existing investors in the Company, namely Venrock […]

Iselin NJ, December 18, 2007 – Pharmos Corporation (Nasdaq: PARS) announced today that President & COO Alan Rubino has elected to resign from the Company. Mr. Rubino joined Pharmos in November 2005 and was instrumental in the strategic acquisition and the subsequent integration of Vela Pharmaceuticals completed in October 2006. Following the Vela acquisition, Mr. Rubino has been focused on key business development priorities and the […]

Company Selected to Participate in Gastroenterology Panel Discussion Iselin NJ, December 10, 2007 – Pharmos Corporation (Nasdaq: PARS) announced today that Chief Executive Officer Elkan R. Gamzu, Ph.D. will participate in a gastroenterology-focused panel discussion at the 2007 RBC Capital Markets Healthcare Conference taking place December 12 – 13, 2007 at the Westin New York at Times Square in New York, New York. The panel is […]

Iselin NJ, November 1, 2007 – Pharmos Corporation (Nasdaq: PARS) announced today that its Chief Executive Officer, Elkan Gamzu, Ph.D., will present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on Monday, November 5, 2007 at 10:55 AM Eastern Time. The conference is taking place November 5-7, 2007 at the New York Palace Hotel in New York, New York. In the presentation, Dr. […]